一分钟看懂
这是一项关于肾细胞癌的III 期研究，登记的药物或干预包括Pembrolizumab；Belzutifan；Pembrolizumab/Quavonlimab；Lenvatinib，当前状态为研究进行中，已停止招募。登记地点显示中国蚌埠、北京、Chongging、福州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pembrolizumab；Belzutifan；Pembrolizumab/Quavonlimab；Lenvatinib · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录7项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Afflilated Hospital of Bengbu Medical College-Urology Surgery ( Site 6041) · 蚌埠
- Cancer Hospital Chinese Academy of Medical Science-Oncology ( Site 6026) · 北京
- Peking University First Hospital ( Site 6011) · 北京
- Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000) · 北京
- Chongqing University Cancer Hospital ( Site 6009) · Chongging
- The First Affiliated Hospital Of Fujian Medical University-Urology ( Site 6038) · 福州
- The First Affiliated Hospital of Xiamen University ( Site 6001) · 厦门
- SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003) · 广州
- The First Affiliated Hospital of Guangzhou Medical University ( Site 6036) · 广州
- Guangzhou First People's Hospital ( Site 6007) · 广州
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University-Urology Surgery ( Site 6005) · 广州
- Harbin Medical University Cancer Hospital-urology ( Site 6015) · 哈尔滨
- Henan Cancer Hospital-Urology ( Site 6006) · 郑州
- Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 6002) · 武汉
- Xiangya Hospital Central South University ( Site 6034) · 长沙
- Hunan Cancer Hospital ( Site 6020) · 长沙
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( Site 6022) · 南京
- The Second Affiliated Hospital of Soochow University-Urology ( Site 6025) · 苏州
- Jiangxi Provincial Cancer Hospital ( Site 6042) · 南昌
- The First Affiliated Hospital of Nanchang University ( Site 6019) · 南昌
- The First Affiliated Hospital of Xi'an Jiaotong University ( Site 6014) · 西安
- Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 6017) · 上海
- Shanghai Tenth People's Hospital ( Site 6023) · 上海
- West China Hospital Sichuan University-Urology Surgery ( Site 6016) · 成都
- Tianjin Medical University Cancer Institute and Hospital ( Site 6029) · 天津
- The Second Hospital of Tianjin Medical University ( Site 6032) · 天津
- The First Affiliated Hospital Zhejiang University School of Medicine ( Site 6024) · 杭州
- The First Hospital of Jiaxing ( Site 6033) · 嘉兴
- Ningbo First Hospital-Urology ( Site 6028) · 宁波
- The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 6021) · 温州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Has histologically confirmed diagnosis of RCC with clear cell component.
- * Has received no prior systemic therapy for advanced ccRCC
- * Male participants are abstinent from heterosexual intercourse or agree to use contraception during and for at least 7 days after last dose of study intervention with belzutifan and lenvatinib.
- * Female participants are not pregnant or breastfeeding and are either not a woman of child-bearing potential (WOCBP) or use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after pembrolizumab or pembrolizumab/quavonlimab or for at least 30 days after last dose of lenvatinib or belzutifan, whichever occurs last
- * Has adequately controlled blood pressure with or without antihypertensive medications
- * Has adequate organ function.
- * Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks prior to randomization/allocation
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04736706；登记信息更新于 2026-10-02；本站同步于 2026-10-08。